Journal of Clinical Oncology
Articles in this Issue
Improving access to pediatric oncology clinical trials: Identifying modifiable enrollment barriers.
e13818 Background: Clinical trial participation is associated with improved childhood cancer outcomes. There are certain groups with less access to pediat...
A phase 1 trial of APX-343A, NOX inhibitor targeting CAF-mediated immunosuppression, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
TPS2697 Background: Cancer-associated fibroblasts (CAFs), a key component of tumor stroma, promote tumor growth and resistance to anticancer therapy. They...
Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1/2 multicenter study.
5051 Background: MHB088C is a novel B7-H3-targeted antibody-drug conjugate (ADC) incorporating the potent SuperTopoi payload, which is 5 to 10 times more...
ITX-0121: A therapeutic strategy for transcription-coupled repair-deficient cancers.
e15149 Background: Cells possess a complex DNA damage response (DDR) system to prevent detrimental mutations from accumulating. The genes encoding various...
The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.
4559 Background: Glucagon-like peptide-1 (GLP-1) receptor agonists have played a pivotal role in the management of type 2 diabetes (T2DM). At the same tim...
Digital spatial profiling: Mapping tumor responses to radiotherapy in rectal cancer.
3593 Background: Variation in response to radiotherapy for the treatment of rectal cancer is likely due to heterogeneity in the tumour microenvironment. H...
Trends in lung cancer epidemiology and mortality over 12 years: Socioeconomic and demographic disparities.
8042 Background: Lung cancer (LC), the most common cancer worldwide, remains a significant health burden with high rate of incidence and mortality in the...
Disruptive advances in exosome lyophilization: Unlocking new frontiers in precision oncology.
e14522 Background: Exosomes derived from pulsed dendritic cells (DEX) are pivotal in regulating the tumor microenvironment (TME), influencing immune respo...
Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer.
524 Background: While breast cancer treatment guidelines provide dosing recommendations, some patients do not receive the full expected dose at outset. Pr...
Do obstructive lung diseases affect outcomes in lung cancer patients?
e20034 Background: Obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD), have a pronounced impact on the outcomes of patie...
Hematology-oncology education in postgraduate internal medicine programs in Nepal: Current status and the pressing need for improvement.
e21020 Background: Cancer accounts for huge non-communicable disease burden in Nepal with majority of patients presenting at an advanced stage accounting...
A multimodal deep learning model for early prediction of pancreatic cancer progression.
e16368 Background: Early and accurate prediction of pancreatic cancer progression is critical for optimizing treatment regimens and improving patient prog...
Platinum or non-platinum therapy in post-olaparib recurrent ovarian cancer: Analysis in matched cohorts.
5588 Background: Due to potential cross-resistance mechanisms efficacy of platinum agents may be dramatically reduced in patients with ovarian cancer whic...
Differential and cumulative impact of metabolic syndrome traits on cardiovascular, renal, and mortality outcomes in cancer patients.
11060 Background: Metabolic syndrome (MetS) is a known risk factor for developing at least 13 cancer types and adverse outcomes. However, the effects of M...
Personalized medicine in colorectal mucinous adenocarcinoma (MAC): Machine learning–based prognostic models.
e15727 Background: MAC accounts for 10% of colorectal cancer cases and is a distinct subtype with poor prognosis and resistance to treatments such as adju...
Global burden and trend of pancreatic cancer in high-income countries: A 30-year analysis of disease dynamics.
10549 Background: Pancreatic cancer (PC) has a disproportionately high impact in high-income countries (HIC), where it ranks as the 3rd leading cause of c...
A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): The SAGITTARIUS trial.
TPS3647 Background: Circulating tumor DNA (ctDNA) testing has emerged as a transformative tool for detecting molecular residual disease (MRD). Multiple pr...
Are indulgent lifestyle practices the driving determinants behind the rising cancer rates in young adult men?
10603 Background: This study aims to determine trends and incidences of cancers associated with social behaviors including tobacco use, excess body fat, a...
AI-powered quantification of tumor-infiltrating lymphocytes from H&E stained images in ovarian cancer and its association with PARP inhibitor therapy outcomes.
5575 Background: Maintenance therapy with PARP inhibitors improves the prognosis of patients with advanced or recurrent ovarian cancer. However, a simple...
Comparative safety and effectiveness of azacitidine plus venetoclax versus intensive chemotherapy in acute myeloid leukemia: A propensity score-matched analysis.
e18509 Background: Azacitidine combined with Venetoclax (HMA&Ven) has been widely used to treat acute myeloid leukemia (AML) in patients over 75 or th...
Evaluation of pancreatic cancer fibrosis based on CT images and its association with chemotherapy efficacy: A multicenter study.
e16444 Background: Tumor fibrosis significantly impacts chemotherapy efficacy in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role remains...
Predicting immune-related adverse events (irAE) in gastrointestinal malignancies (GI-M): Tumor-specific risk factors (TS-RF), hematological markers (HM), and clinical outcomes.
e14652 Background: IrAEs, commonly studied as tumor-agnostic effects of immune checkpoint inhibitors (ICI), require individualization based on baseline (B...
Phase 2 trial of TU2218, TGFβ-RI, and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with biliary tract cancer and head and neck cancer.
TPS2691 Background: TU2218 is a low molecular weight dual kinase inhibitor highly specific to TGFβR1 and VEGFR2 and has a potential to be an efficacious t...
Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.
9565 Background: Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities, usi...
Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study.
e17044 Background: Abiraterone acetate (AA) is a CYP17 inhibitor, an enzyme required for androgen biosynthesis. AA is an approved first-line treatment for...